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Introduction
Axillary lymph node status is still the most important prognostic factor in primary breast cancer despite the development of advanced analysis of prognostic tumour markers (1, 2) .
Histopathological examination after surgical removal of at least ten axillary lymph nodes (ALN) is the standard staging procedure for determination of the axillary lymph node status (3) . Today the sentinel lymph node (SLN) biopsy technique is introduced as an accurate staging procedure for small unifocal breast tumours with clinically negative axilla (4) . For patients without metastases in the SLN, axillary lymph node dissection (ALND) can be omitted and the technique seems to offer minimal arm morbidity without compromising clinical outcome in early-stage breast cancer (4) .
Histopathological examination of the SLN(s) is more detailed than traditional examination of axillary lymph nodes, because the SLN is the only node involved in the majority of patients and the decision on further axillary surgery is based on the status of the SLN (1) . Serial sectioning of the SLN and use of immunohistochemistry (IHC) with cytokeratin have led to increased detection of minimal lymph node involvement classified as micrometastases (>0.2 mm < 2 mm; pN1mi) and isolated tumour cells (ITC) (< 0.2 mm; pN0(i+)) (5) . Initially, nonstandardised protocols for pathological examination of the SLNs were used, but uniform protocols for pathological evaluation of the SLN are currently being developed assuring that the above definitions are being used (1, 6) . Patients with micrometastases are recommended ALND and systemic treatment is advocated to follow the guidelines for node-positive patients, although the exact prognostic role of micrometastatic involvement of the SLN is unknown (2) . Micrometastatic involvement of the ALN is correlated to a worse prognosis compared to node-negative patients in some reports (7, 8) , although this is still an unresolved issue. Regarding SLN micrometastases and relation to clinical outcome, there is limited data based on retrospective examination by IHC of the SLN (9). Patients with ITC are recommended adjuvant treatment as node-negative patients (2) , whereas the role of ALND in this group of patients is still under debate since the risk of additional axillary nodal involvement is yet not clarified (10, 11, 12, 13) .
The aim of the present study was to evaluate the prospective use of IHC in conjunction with serial sectioning and haematoxylin and eosin (HE) staining for SLN examination in relation to the rate of false negative intraoperative cases, stage migration and non-SLN metastases
Material and Methods

Patients
Patients with unifocal primary breast cancer < 3 cm and a clinically negative axilla were The clinicopathological characteristics of the patients are given in Table 1 .
Sentinel lymph node mapping
The sentinel node was identified using radiolabelled isotope (50MBq The axillary lymph nodes were analysed according to the standard protocol at the institution; bisecting nodes larger than 5 mm and stained by HE after fixation and embedding.
Statistical Analyses
The relation between nodal involvement and clinicopathological characteristics was calculated by Chi-square test for categorised variables and by Kruskal-Wallis test for continuous variables.
Recurrence free survival was defined as local, distant or breast cancer specific death as primary event. The Cox Proportional Hazards Model was used for estimation of univariate hazard ratios (HRs).
All calculations were performed in SPSS version 11.0. (SPSS inc., Ill., USA).
Results
Diagnosis of SLN metastases and isolated tumour cells
One or more SLNs were detected in all but one patient who had metastatic growth in fourteen axillary lymph nodes, giving a detection rate of (173/174) in this cohort. The median number of SLNs examined was 2 (range 0-6) and 26/173 patients had metastatic involvement (Table 2) .
Intraoperative false negative rate
The false negative rates for intraoperative diagnosis of metastases in the SLN for macrometastases, micrometastases and ITC using IHC are given in Table 2 . The micrometastases diagnosed by FS exceeded 1.00 mm in diameter, whereas no ITC was diagnosed intraoperatively. There was no statistically significant difference in the rate of IHC-detected tumour involvement in relation to histopathological subgroups (i.e. ductal 5/123, lobular 2/38, tubular 0/9 or mixed 0/3, p=0.7).
Stage migration and IHC
Stage migration from N0 to N1mi after definitive histopathological diagnosis including IHC was noted in 3/132 patients diagnosed as N0 by use of HE (Table 2 ). In addition, the fraction of patients classified as N0(i+) increased from 2 by HE to 6 by HE and IHC.
Non SLN metastases
All patients with a metastatic foci in the SLN, including patients with ITC, had an ALND including level I-II harvesting in median 13 nodes with no difference in the number of analysed ALNs between the three groups ( Table 2) . Non-SLN metastases were found in 15/28 of patients with macrometastases, whereas 3/16 of patients with micrometastases had additional metastatic nodal involvement and 0/6 of the patients with ITC had a non-SLN metastasis (p=0.007). All patients diagnosed with more than one positive SLN had non-SLN metastases. One of the N1mi diagnosed by IHC measuring 1.00 mm had a non-SLN metastasis.
Relation between clinicopathological characteristics and lymph node status
Tumour size and PR negativity were related to metastatic SLN involvement, whereas histological grade, histopathological type and age were not (Table 1) .
Clinical outcome
After a median of follow-up36 months (0-56 months, mean 37 months), ten relapses and nine deaths were recorded. Six breast cancer related deaths were diagnosed, two due to other malignancies (lung and haematological) and one due to liver disease. The recurrence free survival (RFS) for node-positive patients (n=28) was 86%, with four distant recurrences.
Three patients died of breast cancer after diagnosis of a distant recurrence. For the 16 patients with micrometastases in the SLN, one distant recurrence was recorded (94% RFS), but no breast-cancer-related death occurred. For node-negative patients not classified as N0(i+) (n=123), four distant recurrences were diagnosed (97% RFS) and three patients died of breast cancer. There rate of distant recurrences were significantly related to the SLN status defined as N1, N1mi and N0 (Table 1) . Within the ITC group (n=6), one local recurrence within a mastectomy scar was diagnosed but no distant recurrence or breast-cancer-related death. No axillary recurrence was recorded in any group including the N0 patients.
Using the Cox Proportional Hazards Univariate analyses tumour size (T2 vs T1), Nottingham histological grade (III vs I-II), number of involved nodes, non-SLN metastases and nodal
metastatic size were predictors of breast cancer recurrence and death (Table 3) .
Discussion
Protocols for histpopathological diagnosis of SLNs
The introduction of the SLN biopsy technique for T1-T2 breast cancer as a staging procedure is justified by the low false negative rate of detecting SLN and SLN is accepted as a reliable method for evaluation of axillary node status in this group of patients (4 
Stage migration by use of IHC
In line with the finding in this study that prospective use of IHC detected additional metastatic SLN infiltration at a low rate, stage migration from N0 to N1mi by cytokeratin staining was noted in 3/132 of N0 patients. Stage migration is previously reported to be a significant finding associated with IHC protocols, extended to a larger fraction of patients (9% or more) initially diagnosed as node-negative (13, 21) . Using the protocol described, the prospective use of IHC had a minimal impact on stage migration and treatment decisions, supporting data in a recent publication (19) . All macrometastases were diagnosed by HE, whereas 4/6 of patients diagnosed with ITC were detected by IHC and thus upstaged to N0(i+).
Risk of non SLN metastases
Non-SLN metastatic involvement is correlated to the size of the metastatic lesion in the SLN and ALND is therefore recommended for all patients with N1 disease (1, 2). 
